Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asher Goldstein

Pain Medicine Hackensack, NJ Medical Doctor

NPI 1790725661 CMS profile 262367

160 Overlook Ave, Ste 1A, Hackensack, NJ 07601

Open in the dashboard

General payments

$8,131

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asher Goldstein of Hackensack, NJ is reported in the CMS Open Payments database as having received $8,131 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,232 36
2024 General $334 8
2023 General $2,801 23
2022 General $118 4
2021 General $922 12
2020 General $99 7
2019 General $625 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asher Goldstein
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Asher Goldstein were reported at $3,232. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Asher Goldstein Pain Medicine median Middle half National median
2019 $625 $409 $115–$1,311 $163
2020 $99 $214 $66–$666 $114
2021 $922 $299 $84–$899 $132
2022 $118 $335 $103–$1,149 $149
2023 $2,801 $376 $114–$1,228 $160
2024 $334 $387 $115–$1,173 $164
2025 $3,232 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $3,105 15 payments
  2. Saluda Medical Americas, Inc. $2,383 23 payments
  3. Abbott Laboratories $451 18 payments
  4. Curonix LLC $243 3 payments
  5. SPR Therapeutics, Inc $228 6 payments
  6. MML US, Inc. $228 8 payments
  7. Spinal Simplicity, LLC $202 3 payments
  8. Boston Scientific Corporation $183 5 payments
  9. Nalu Medical, Inc. $177 2 payments
  10. Medtronic, Inc. $172 2 payments
  11. Other $759 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,914 107 payments
  2. Travel and Lodging $3,178 5 payments
  3. Education $38 2 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $2,402 13 payments
  2. Intracept Pain $2,364 12 payments
  3. Intracept Pain $2,364 12 payments
  4. Intracept Pain $2,364 12 payments
  5. Evoke $2,340 22 payments
  6. Intracept Pain $741 3 payments
  7. Intracept Pain $741 3 payments
  8. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $243 3 payments
  9. SPRINT PNS System $228 6 payments
  10. ReActiv8 $228 8 payments
  11. Other $1,825 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,316

Median for Pain Management: 951

Drug cost

$57,600

Median for Pain Management: $26,034

Branded share of claims

26.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 22 $15,213
Buprenorphine Generic 73 $13,250
Xtampza Er Oxycodone Myristate Brand 11 $7,953
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 253 $5,289
Oxycodone Hcl Generic 191 $3,859
Gabapentin Generic 173 $1,904
Fentanyl Generic 33 $1,800
Naproxen Generic 77 $1,433
Celecoxib Generic 43 $1,410
Cyclobenzaprine Hcl Generic 59 $1,106

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$67,891

Medicare's payments for the services billed

Medicare patients

124

Average age 71

Services billed

679

74 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Depression 35%
Ischemic heart disease 27%
Osteoporosis 27%
Chronic kidney disease 22%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record